PRESS RELEASES

Date	Title
Oct 13, 2021	Ardelyx Provides Corporate Update Following Type A Meeting with FDA
Sep 3, 2021	Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial
Aug 13, 2021	Ardelyx Reports Second Quarter 2021 Financial Results
Jul 29, 2021	Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
Jul 19, 2021	Ardelyx Provides Regulatory Update on New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
Jun 7, 2021	Ardelyx Announces Presentations at ERA-EDTA Virtual Congress 2021
May 25, 2021	Ardelyx to Present at the Jefferies 2021 Virtual Healthcare Conference
May 6, 2021	Ardelyx Reports First Quarter 2021 Financial Results and Recent Business Highlights
Apr 29, 2021	Ardelyx Announces Extension of the PDUFA Review Period for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
Apr 16, 2021	Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 617.675.ARDX (2739)

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com